Eric R. Olson is CSO at Syros Pharmaceuticals, Inc. (SYRS). They have made 3 open-market trades across 1 company since 2017, most recently 2023-07-17.
CIK 0001678149
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| SYRS | 6,661 | $799 |
Shares reported on the most recent Form 4, priced at the 2023-07-18 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SYRS | SELL · 10b5-1 | 2023-07-17 | 2023-07-18 | $3.50 | $2K | +5.0% | +13.7% | -37.2% |
| SYRS | SELL · 10b5-1 | 2022-01-05 | 2022-01-06 | $3.47 | $8K | -32.0% | -49.9% | -69.5% |
| SYRS | SELL · 10b5-1 | 2021-07-01 | 2021-07-01 | $5.55 | $6K | -18.9% | -16.9% | -23.3% |
| SYRS | SELL · 10b5-1 | 2021-03-15 | 2021-03-17 | $9.47 | $34K | -16.3% | -30.0% | -35.4% |
| SYRS | SELL | 2020-08-17 | 2020-08-19 | $13.00 | $205K | -4.9% | -28.2% | -40.2% |
| SYRS | SELL · 10b5-1 | 2020-07-07 | 2020-07-07 | $11.72 | $21K | +3.0% | +3.4% | -22.3% |
| SYRS | SELL · 10b5-1 | 2020-02-18 | 2020-02-20 | $7.38 | $11K | -20.7% | -21.5% | +33.5% |
| SYRS | SELL | 2017-08-07 | 2017-08-08 | $23.59 | $59K | -11.5% | -25.4% | -38.5% |
| SYRS | SELL | 2017-07-25 | 2017-07-27 | $21.85 | $273K | +10.7% | -2.8% | -19.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.